nodes	percent_of_prediction	percent_of_DWPC	metapath
Propylthiouracil—Lung infiltration—Fludarabine—lymphatic system cancer	0.0376	0.0376	CcSEcCtD
Propylthiouracil—Skin ulcer—Mechlorethamine—lymphatic system cancer	0.035	0.035	CcSEcCtD
Propylthiouracil—Lung infiltration—Bleomycin—lymphatic system cancer	0.0276	0.0276	CcSEcCtD
Propylthiouracil—Lung infiltration—Carmustine—lymphatic system cancer	0.0241	0.0241	CcSEcCtD
Propylthiouracil—Interstitial pneumonia—Mitoxantrone—lymphatic system cancer	0.0217	0.0217	CcSEcCtD
Propylthiouracil—Interstitial lung disease—Bleomycin—lymphatic system cancer	0.0183	0.0183	CcSEcCtD
Propylthiouracil—Allergic cutaneous angiitis—Methotrexate—lymphatic system cancer	0.0164	0.0164	CcSEcCtD
Propylthiouracil—Interstitial lung disease—Carmustine—lymphatic system cancer	0.016	0.016	CcSEcCtD
Propylthiouracil—Jaundice—Mechlorethamine—lymphatic system cancer	0.0148	0.0148	CcSEcCtD
Propylthiouracil—Interstitial lung disease—Mitoxantrone—lymphatic system cancer	0.0148	0.0148	CcSEcCtD
Propylthiouracil—Neuritis—Vincristine—lymphatic system cancer	0.0144	0.0144	CcSEcCtD
Propylthiouracil—Hepatic failure—Fludarabine—lymphatic system cancer	0.0143	0.0143	CcSEcCtD
Propylthiouracil—Agranulocytosis—Mechlorethamine—lymphatic system cancer	0.0142	0.0142	CcSEcCtD
Propylthiouracil—Haemoglobin—Mechlorethamine—lymphatic system cancer	0.0137	0.0137	CcSEcCtD
Propylthiouracil—Haemorrhage—Mechlorethamine—lymphatic system cancer	0.0137	0.0137	CcSEcCtD
Propylthiouracil—Alopecia—Mechlorethamine—lymphatic system cancer	0.0121	0.0121	CcSEcCtD
Propylthiouracil—Lung infiltration—Methotrexate—lymphatic system cancer	0.0112	0.0112	CcSEcCtD
Propylthiouracil—Neuropathy peripheral—Teniposide—lymphatic system cancer	0.011	0.011	CcSEcCtD
Propylthiouracil—Interstitial pneumonia—Methotrexate—lymphatic system cancer	0.0108	0.0108	CcSEcCtD
Propylthiouracil—Vertigo—Mechlorethamine—lymphatic system cancer	0.0107	0.0107	CcSEcCtD
Propylthiouracil—Leukocytoclastic vasculitis—Methotrexate—lymphatic system cancer	0.0107	0.0107	CcSEcCtD
Propylthiouracil—Leukopenia—Mechlorethamine—lymphatic system cancer	0.0107	0.0107	CcSEcCtD
Propylthiouracil—Haemoglobin—Teniposide—lymphatic system cancer	0.0101	0.0101	CcSEcCtD
Propylthiouracil—Haemorrhage—Teniposide—lymphatic system cancer	0.0101	0.0101	CcSEcCtD
Propylthiouracil—Neuropathy peripheral—Fludarabine—lymphatic system cancer	0.00968	0.00968	CcSEcCtD
Propylthiouracil—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00951	0.00951	CcSEcCtD
Propylthiouracil—Alopecia—Teniposide—lymphatic system cancer	0.00891	0.00891	CcSEcCtD
Propylthiouracil—Haemoglobin—Fludarabine—lymphatic system cancer	0.00891	0.00891	CcSEcCtD
Propylthiouracil—Haemorrhage—Fludarabine—lymphatic system cancer	0.00886	0.00886	CcSEcCtD
Propylthiouracil—Hepatic failure—Vincristine—lymphatic system cancer	0.00871	0.00871	CcSEcCtD
Propylthiouracil—Renal failure acute—Mitoxantrone—lymphatic system cancer	0.00825	0.00825	CcSEcCtD
Propylthiouracil—Leukopenia—Teniposide—lymphatic system cancer	0.00786	0.00786	CcSEcCtD
Propylthiouracil—Alopecia—Fludarabine—lymphatic system cancer	0.00783	0.00783	CcSEcCtD
Propylthiouracil—Interstitial lung disease—Methotrexate—lymphatic system cancer	0.00739	0.00739	CcSEcCtD
Propylthiouracil—Oedema—Teniposide—lymphatic system cancer	0.00716	0.00716	CcSEcCtD
Propylthiouracil—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00701	0.00701	CcSEcCtD
Propylthiouracil—Leukopenia—Fludarabine—lymphatic system cancer	0.0069	0.0069	CcSEcCtD
Propylthiouracil—Pruritus—Mechlorethamine—lymphatic system cancer	0.00687	0.00687	CcSEcCtD
Propylthiouracil—Skin ulcer—Methotrexate—lymphatic system cancer	0.00672	0.00672	CcSEcCtD
Propylthiouracil—Arthralgia—Fludarabine—lymphatic system cancer	0.00657	0.00657	CcSEcCtD
Propylthiouracil—Myalgia—Fludarabine—lymphatic system cancer	0.00657	0.00657	CcSEcCtD
Propylthiouracil—Haemoglobin—Bleomycin—lymphatic system cancer	0.00653	0.00653	CcSEcCtD
Propylthiouracil—Haemorrhage—Bleomycin—lymphatic system cancer	0.0065	0.0065	CcSEcCtD
Propylthiouracil—Oedema—Fludarabine—lymphatic system cancer	0.0063	0.0063	CcSEcCtD
Propylthiouracil—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.00619	0.00619	CcSEcCtD
Propylthiouracil—Vomiting—Mechlorethamine—lymphatic system cancer	0.00618	0.00618	CcSEcCtD
Propylthiouracil—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00616	0.00616	CcSEcCtD
Propylthiouracil—Rash—Mechlorethamine—lymphatic system cancer	0.00613	0.00613	CcSEcCtD
Propylthiouracil—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00612	0.00612	CcSEcCtD
Propylthiouracil—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00591	0.00591	CcSEcCtD
Propylthiouracil—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00587	0.00587	CcSEcCtD
Propylthiouracil—Nausea—Mechlorethamine—lymphatic system cancer	0.00577	0.00577	CcSEcCtD
Propylthiouracil—Alopecia—Bleomycin—lymphatic system cancer	0.00574	0.00574	CcSEcCtD
Propylthiouracil—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00574	0.00574	CcSEcCtD
Propylthiouracil—Jaundice—Mitoxantrone—lymphatic system cancer	0.00572	0.00572	CcSEcCtD
Propylthiouracil—Haemoglobin—Carmustine—lymphatic system cancer	0.0057	0.0057	CcSEcCtD
Propylthiouracil—Urticaria—Teniposide—lymphatic system cancer	0.00569	0.00569	CcSEcCtD
Propylthiouracil—Haemorrhage—Carmustine—lymphatic system cancer	0.00567	0.00567	CcSEcCtD
Propylthiouracil—Body temperature increased—Teniposide—lymphatic system cancer	0.00566	0.00566	CcSEcCtD
Propylthiouracil—Paraesthesia—Fludarabine—lymphatic system cancer	0.00565	0.00565	CcSEcCtD
Propylthiouracil—Dyspepsia—Fludarabine—lymphatic system cancer	0.00554	0.00554	CcSEcCtD
Propylthiouracil—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00548	0.00548	CcSEcCtD
Propylthiouracil—Vasculitis—Methotrexate—lymphatic system cancer	0.00536	0.00536	CcSEcCtD
Propylthiouracil—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.0053	0.0053	CcSEcCtD
Propylthiouracil—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00527	0.00527	CcSEcCtD
Propylthiouracil—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00527	0.00527	CcSEcCtD
Propylthiouracil—Pruritus—Teniposide—lymphatic system cancer	0.00507	0.00507	CcSEcCtD
Propylthiouracil—Leukopenia—Bleomycin—lymphatic system cancer	0.00506	0.00506	CcSEcCtD
Propylthiouracil—Alopecia—Carmustine—lymphatic system cancer	0.00501	0.00501	CcSEcCtD
Propylthiouracil—Body temperature increased—Fludarabine—lymphatic system cancer	0.00498	0.00498	CcSEcCtD
Propylthiouracil—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.00491	0.00491	CcSEcCtD
Propylthiouracil—Myalgia—Bleomycin—lymphatic system cancer	0.00481	0.00481	CcSEcCtD
Propylthiouracil—Alopecia—Vincristine—lymphatic system cancer	0.00478	0.00478	CcSEcCtD
Propylthiouracil—Alopecia—Mitoxantrone—lymphatic system cancer	0.00466	0.00466	CcSEcCtD
Propylthiouracil—Oedema—Bleomycin—lymphatic system cancer	0.00462	0.00462	CcSEcCtD
Propylthiouracil—Vomiting—Teniposide—lymphatic system cancer	0.00455	0.00455	CcSEcCtD
Propylthiouracil—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00452	0.00452	CcSEcCtD
Propylthiouracil—Rash—Teniposide—lymphatic system cancer	0.00452	0.00452	CcSEcCtD
Propylthiouracil—Dermatitis—Teniposide—lymphatic system cancer	0.00451	0.00451	CcSEcCtD
Propylthiouracil—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00449	0.00449	CcSEcCtD
Propylthiouracil—Headache—Teniposide—lymphatic system cancer	0.00449	0.00449	CcSEcCtD
Propylthiouracil—Pruritus—Fludarabine—lymphatic system cancer	0.00445	0.00445	CcSEcCtD
Propylthiouracil—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.00445	0.00445	CcSEcCtD
Propylthiouracil—Leukopenia—Carmustine—lymphatic system cancer	0.00442	0.00442	CcSEcCtD
Propylthiouracil—Nausea—Teniposide—lymphatic system cancer	0.00425	0.00425	CcSEcCtD
Propylthiouracil—Vertigo—Vincristine—lymphatic system cancer	0.00423	0.00423	CcSEcCtD
Propylthiouracil—Hepatic failure—Methotrexate—lymphatic system cancer	0.00423	0.00423	CcSEcCtD
Propylthiouracil—Leukopenia—Vincristine—lymphatic system cancer	0.00422	0.00422	CcSEcCtD
Propylthiouracil—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00421	0.00421	CcSEcCtD
Propylthiouracil—Myalgia—Carmustine—lymphatic system cancer	0.0042	0.0042	CcSEcCtD
Propylthiouracil—Paraesthesia—Bleomycin—lymphatic system cancer	0.00414	0.00414	CcSEcCtD
Propylthiouracil—Renal failure acute—Methotrexate—lymphatic system cancer	0.00411	0.00411	CcSEcCtD
Propylthiouracil—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00411	0.00411	CcSEcCtD
Propylthiouracil—Oedema—Carmustine—lymphatic system cancer	0.00403	0.00403	CcSEcCtD
Propylthiouracil—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.00402	0.00402	CcSEcCtD
Propylthiouracil—Myalgia—Vincristine—lymphatic system cancer	0.00401	0.00401	CcSEcCtD
Propylthiouracil—Vomiting—Fludarabine—lymphatic system cancer	0.004	0.004	CcSEcCtD
Propylthiouracil—Rash—Fludarabine—lymphatic system cancer	0.00397	0.00397	CcSEcCtD
Propylthiouracil—Dermatitis—Fludarabine—lymphatic system cancer	0.00397	0.00397	CcSEcCtD
Propylthiouracil—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00394	0.00394	CcSEcCtD
Propylthiouracil—Headache—Fludarabine—lymphatic system cancer	0.00394	0.00394	CcSEcCtD
Propylthiouracil—Myalgia—Mitoxantrone—lymphatic system cancer	0.00391	0.00391	CcSEcCtD
Propylthiouracil—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00391	0.00391	CcSEcCtD
Propylthiouracil—Oedema—Vincristine—lymphatic system cancer	0.00385	0.00385	CcSEcCtD
Propylthiouracil—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00377	0.00377	CcSEcCtD
Propylthiouracil—Oedema—Mitoxantrone—lymphatic system cancer	0.00375	0.00375	CcSEcCtD
Propylthiouracil—Nausea—Fludarabine—lymphatic system cancer	0.00374	0.00374	CcSEcCtD
Propylthiouracil—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00367	0.00367	CcSEcCtD
Propylthiouracil—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00367	0.00367	CcSEcCtD
Propylthiouracil—Urticaria—Bleomycin—lymphatic system cancer	0.00367	0.00367	CcSEcCtD
Propylthiouracil—Body temperature increased—Bleomycin—lymphatic system cancer	0.00365	0.00365	CcSEcCtD
Propylthiouracil—Paraesthesia—Carmustine—lymphatic system cancer	0.00362	0.00362	CcSEcCtD
Propylthiouracil—Somnolence—Carmustine—lymphatic system cancer	0.00358	0.00358	CcSEcCtD
Propylthiouracil—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.0035	0.0035	CcSEcCtD
Propylthiouracil—Paraesthesia—Vincristine—lymphatic system cancer	0.00345	0.00345	CcSEcCtD
Propylthiouracil—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00341	0.00341	CcSEcCtD
Propylthiouracil—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00336	0.00336	CcSEcCtD
Propylthiouracil—Somnolence—Mitoxantrone—lymphatic system cancer	0.00333	0.00333	CcSEcCtD
Propylthiouracil—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.0033	0.0033	CcSEcCtD
Propylthiouracil—Pruritus—Bleomycin—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Propylthiouracil—Body temperature increased—Carmustine—lymphatic system cancer	0.00318	0.00318	CcSEcCtD
Propylthiouracil—Body temperature increased—Vincristine—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Propylthiouracil—Urticaria—Mitoxantrone—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Propylthiouracil—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00296	0.00296	CcSEcCtD
Propylthiouracil—Vomiting—Bleomycin—lymphatic system cancer	0.00293	0.00293	CcSEcCtD
Propylthiouracil—Drowsiness—Methotrexate—lymphatic system cancer	0.00293	0.00293	CcSEcCtD
Propylthiouracil—Rash—Bleomycin—lymphatic system cancer	0.00291	0.00291	CcSEcCtD
Propylthiouracil—Dermatitis—Bleomycin—lymphatic system cancer	0.00291	0.00291	CcSEcCtD
Propylthiouracil—Nausea—Bleomycin—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Propylthiouracil—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00273	0.00273	CcSEcCtD
Propylthiouracil—Haemoglobin—Methotrexate—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Propylthiouracil—Hepatitis—Methotrexate—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Propylthiouracil—Haemorrhage—Methotrexate—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Propylthiouracil—Vomiting—Carmustine—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Propylthiouracil—Rash—Carmustine—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Propylthiouracil—Dermatitis—Carmustine—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Propylthiouracil—Headache—Carmustine—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Propylthiouracil—Vomiting—Vincristine—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Propylthiouracil—Rash—Vincristine—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Propylthiouracil—Dermatitis—Vincristine—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Propylthiouracil—Headache—Vincristine—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Propylthiouracil—Nausea—Carmustine—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Propylthiouracil—Vomiting—Mitoxantrone—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Propylthiouracil—Rash—Mitoxantrone—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Propylthiouracil—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Propylthiouracil—Headache—Mitoxantrone—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Propylthiouracil—Alopecia—Methotrexate—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Propylthiouracil—Nausea—Vincristine—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Propylthiouracil—Dysgeusia—Methotrexate—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Propylthiouracil—Nausea—Mitoxantrone—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Propylthiouracil—Vertigo—Methotrexate—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Propylthiouracil—Leukopenia—Methotrexate—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Propylthiouracil—Myalgia—Methotrexate—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Propylthiouracil—Arthralgia—Methotrexate—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Propylthiouracil—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Propylthiouracil—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Propylthiouracil—Paraesthesia—Methotrexate—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Propylthiouracil—Somnolence—Methotrexate—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Propylthiouracil—Dyspepsia—Methotrexate—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Propylthiouracil—Urticaria—Methotrexate—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Propylthiouracil—Body temperature increased—Methotrexate—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Propylthiouracil—Pruritus—Methotrexate—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Propylthiouracil—Vomiting—Methotrexate—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Propylthiouracil—Rash—Methotrexate—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Propylthiouracil—Dermatitis—Methotrexate—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Propylthiouracil—Headache—Methotrexate—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Propylthiouracil—Nausea—Methotrexate—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
